5. Eylea

Eylea
Regeneron's Eylea is already duking it out in the ophthalmology arena with Novartis' Beovu. Meanwhile, a wave of biosims could soon crash down. (Regeneron)

Eylea
Company:
 Regeneron, Bayer
2020 sales: $8.36 billion
Key patent expirations: 2025 to 2026

5. Eylea